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BACKGROUND: Prognostic value of proton MR spectroscopy (H-MRS) in hypoxic–ischemic encephalopathy (HIE) is acknowledged;
however, effects of gestational age (GA) and postnatal age (PA) on prediction and metabolite levels are unknown.
METHODS: One hundred and sixty-nine newborns with moderate-to-severe HIE were studied, having ≥1 H-MRS scan during
postnatal days 0–14 and known neurodevelopmental outcome (Bayley-II score/cerebral palsy/death). Initial scans were categorized
by PA (day 1–3/4–6/≥7), and metabolite ratios were compared by predictive value. Metabolite dynamics were assessed in a total of
214 scans performed in the study population, using regression modeling, with predictors GA, PA, and outcome.
RESULTS: N-acetyl-aspartate (NAA)/creatine (Cr) and myo-inositol (mI)/NAA height ratios were consistently associated with
outcome throughout the first 14 days, with the highest predictive value in the late (≥7 days) period (AUC= 0.963 and 0.816,
respectively). Neither GA nor PA had an overall effect on these metabolite ratios, which showed strongest association with outcome
(p < 0.001). Assessed separately in patients with good outcome, GA became a significant covariate for metabolite ratios (p= 0.0058
and 0.0002, respectively). However, this association disappeared in the poor outcome group.
CONCLUSIONS: In HIE, NAA/Cr and mI/NAA give most accurate outcome prediction throughout postnatal days 0–14. GA only
affected metabolite levels in the good outcome group.
Pediatric Research; https://doi.org/10.1038/s41390-021-01626-z
IMPACT:
● Proton MR spectroscopy metabolite ratios N-acetyl-aspartate/creatine and myo-inositol/N-acetyl-aspartate have persistently
high predictive value throughout postnatal days 0–14 in newborns with hypoxic–ischemic encephalopathy, with the highest
predictive power between postnatal days 7 and 14.
● Overall, neither metabolite ratio was affected by gestational age nor by postnatal age, while they showed the strongest
association with neurological outcome.
● However, in newborns facing good outcome, metabolite ratios were associated with gestational age, whereas in cases facing
poor outcome, this association disappeared.
● Proton MR spectroscopy provides valuable prognostic information in neonatal hypoxic–ischemic encephalopathy throughout
the first 2 weeks of life, irrespective of the timing of MR scan.
INTRODUCTION
Neonatal hypoxic–ischemic encephalopathy (HIE) affects 1–2‰ of
newborns in the developed countries and is one of the leading
causes of permanent neurological handicap1. A wide variety of
neuroprotective therapies are emerging, additional to the current
gold standard therapeutic hypothermia, emphasizing the need for
early outcome prediction for risk stratification strategies2,3.
Brain proton magnetic resonance spectroscopy (H-MRS) is one
of the most accurate tools for predicting long-term neurodevelop-
mental outcome in HIE, especially during the first weeks of life4,5.
Recent evidence suggests that the prognostic accuracy of H-MRS
is not equal in the period between postnatal hours 18–96 and
postnatal days 7–146. However, the effect of the newborns’
postnatal age on the predictive value of H-MRS throughout the
first weeks of life has not been studied in detail, albeit
examination of all newborns with HIE in a uniform postnatal
narrow age window is not plausible, due to variable clinical
stability and available resources. Moreover, existing evidence
proposes that metabolite ratios may also be affected by
gestational age7. The influence of neither of these factors has
been studied so far on the predictive value of H-MRS, even though
accurate description of metabolite dynamics would be essential,
especially by investigating metabolite ratios registered conven-
tionally, to ensure generalizability.
Thus, the purpose of our study was to determine whether
H-MRS is a suitable predictive tool throughout days of life 0–14
with particular interest in the effect of postnatal age at H-MRS
scan on the accuracy of outcome prediction in newborns with HIE.
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Additionally, we aimed to investigate how gestational age and




In our retrospective analysis, we reviewed all 484 consecutive patients
diagnosed with moderate-to-severe HIE according to the criteria of the
international TOBY trial8, born between January 2006 and December 2016,
and admitted to the regional cooling center, the Neonatal Intensive Care
Unit (NICU) of the 1st Department of Paediatrics, Semmelweis University,
Budapest, Hungary. Prospective consent was obtained from parents/legal
guardians of all newborns participating in our study. Ethical permission for
the analysis was obtained from the Scientific and Medical Research Council
Ethics Committee of Hungary (11790-2/2016/EKU).
Inclusion criteria were (A) having at least one brain H-MRS examination
performed during the first 14 days of life and (B) having a neurodevelop-
mental follow-up examination result, as detailed below OR death (<28 days
of life OR >28 days associated with HIE). Exclusion criteria were (c)
gestational age <36 weeks OR (d) other underlying conditions for
encephalopathy besides HIE (i.e., stroke, intracranial hemorrhage, con-
genital malformation, or metabolic disease) OR (e) lack of hypothermia
treatment OR (f) low-quality brain H-MRS scan. The algorithm for patient
selection is presented in Fig. 1.
Clinical care of newborns
Whole-body hypothermia treatment was initiated as soon as possible but
within 6 h after delivery using a water-filled mattress (Tecotherm©;
TecCom, Halle, Germany). The target rectal temperature was between 33
and 34 °C, maintained for 72 h. In the rewarming phase, temperature
increase velocity was 0.5 °C/h. All infants were invasively ventilated
throughout the cooling and rewarming phase and were extubated
following rewarming. Sedation was provided using continuous morphine
infusion, and clinical or electrophysiological seizures were treated with
phenobarbitone and midazolam, if necessary.
Clinical care of the newborns was performed according to our unit’s
protocol for HIE in the examined time period, described in detail in our
previous study9. Neurological staging was performed according to the
modified Sarnat amplitude-integrated electroencephalography (aEEG)
scoring system, as follows: moderate encephalopathy was defined as
moderately abnormal aEEG pattern (discontinuous normal voltage) on
<6 h aEEG AND Sarnat stage 1–2, severe encephalopathy was defined as
severely abnormal (burst suppression (BS), low voltage (LV), or flat trace
(FT)) on <6 h aEEG OR Sarnat 310. In case of hemodynamic instability,
infants received cardiovascular support (dobutamine, dopamine, norepi-
nephrine, epinephrine, hydrocortisone, or milrinone) and invasive
ventilation.
H-MRS examination
H-MRS studies were carried out as part of the routine MR examination on a
3-Tesla Philips Achieva magnetic resonance imaging (MRI) scanner
between 2006 January and 2015 November and on a 3-Tesla Philips
Ingenia MRI scanner between 2015 December and 2016 December (Philips
Medical Systems, Best, The Netherlands) at the Department of Neuror-
adiology of the Medical Imaging Centre, Semmelweis University, as early as
the infant reached clinical stability and was suitable for transport. Control
MR and H-MRS were performed at a later age, if needed. The MR scans
were performed between days of life (DOL) 1 and 14 (median 4).
The Neonatal Emergency & Transport Services of the Peter Cerny
Foundation provided the neonatal transport and the critical care, including
hypothermia treatment and sedation during MR scanning. Continuous
monitoring of transcutaneous oxygen saturation and capnography was
provided for all neonates during the MR scan, using Medrad Veris MR
Monitoring System (Bayer Healthcare LLC, Whippany, NJ). During the MR
examination, passive hypothermia was provided (bare infants, covered
only with a blanket), considering the relatively cool room temperature of
the MR examination room. Pre-scan and post-scan core temperature was
checked per protocol, and no deviation larger than ±0.5 °C was detected.
Acquisition protocols
Proton MR spectra were acquired using the PRESS (Point RESolved
Spectroscopy) single-voxel localization sequence, at an intermediate echo
time (TE) of 144ms, repetition time (TR)= 2000, number of signal
acquisitions (NSA)= 128. Duration of scan was approximately 30min.
The analyzed volume of interest was a 1 × 1 × 1 cm voxel in the left
thalamus of infants, localized based on gradient echo survey images
acquired with TE= 5ms, TR= 75ms, and 30° flip angle (Fig. 2a). For
analysis of the acquired spectra, we used the vendor-provided data-
processing software on the MR console, “Spektroview,” and its generic
scripts, consisting of the following data-processing steps: (1) Initial Baseline
Subtraction (only on 144 and 288ms TEs), (2) Peak Selection
(where all possible peaks were selected, except the water peak), (3) Peak
Fitting (Analysis range [−1; 4.35] ppm, Visualized range [0; 4.35]
ppm, Baseline Terms: 7; Gaussian Character [%]: 90), (4) Phase: Real,
(5) Lock relative frequency option: ON (this enables for more robust peak
fitting, by detecting the individual peaks using their known difference of
frequency), (6) Lock width option: OFF (peak width is freely fitted by the
software).
Representative spectra of newborns facing good and poor outcome are
presented in Fig. 2b, c.
Metabolite ratios
For quality assurance of the registered H-MRS, only spectral data of peaks
with sufficiently high signal-to-noise ratio (>2) were included in our
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Fig. 1 Algorithm of patient selection for our study, detailing
inclusion and exclusion criteria. aAge at scan categorization was
done based on the initial performed H-MRS scan, where more than
one was performed. bInitial and control H-MRS spectra were also
included, without age at scan categorization. ROC receiver-
operating characteristics.















analysis. From the registered H-MRS spectrum, we analyzed the metabolite
ratios showing high predictive power in newborns with HIE when
registered conventionally, according to existing research results: N-
acetyl-aspartate (NAA)/creatine (Cr), NAA/choline (Cho), and myo-inositol
(mI)/NAA ratios9. Both ratios of peak height and ratios of peak areas were
analyzed, due to their similar reliability in case of conventional H-MRS
sequence11.
Postnatal age categories
For analysis of optimal postnatal age at H-MRS for outcome prediction, first
acquired H-MRS results were categorized based on postnatal age at scan,
given in DOL, as follows: (I) early H-MRS (DOL 1–3), (II) midtime H-MRS
(DOL 4–6) and (III) late H-MRS (DOL ≥7)12.
In the analysis of metabolite ratio dynamics, initial and control
H-MRS results were also included, without the above-described age
categorization.
Follow-up
Neurodevelopmental follow-up was measured by Bayley Scales of Infant
Development II tool-kit (BSID-II) on all patients performed between 18 and
26 months of age by trained personnel blinded to the H-MRS results. We
defined poor outcome as a composite of either death (<28 days of age OR
>28 days associated with HIE) OR moderately/severely delayed develop-
ment (Mental Developmental Index (MDI) or Psychomotor Developmental
Index (PDI) <70). In children where BSID-II was not feasible due to severe
disability, diagnosed cerebral palsy OR bilateral cortical visual impairment
with no useful vision OR bilateral sensorineural hearing loss constituted the
poor outcome. All other outcomes were considered as good outcome.
Statistical analysis
Categorical variables are reported as absolute numbers and percentages,
while continuous variables as mean ± standard deviation or median [25th



















































Fig. 2 Representative H-MRS spectra of newborns with moderate-to-severe HIE. a Gradient echo survey images acquired with echo time
(TE)= 5ms, repetition time (TR)= 75ms, and 30° flip angle for selection of volume of interest (VOI) from the left thalamus of infants (red
frame). b H-MRS of newborn who later had good outcome at TE= 144ms. c H-MRS of newborn who later had poor outcome at TE= 144ms.
Cho choline, Cr creatine, Cr2 creatine, second peak, Lac lactate, doublet peak, mI myo-inositol, doublet peak, NAA N-acetyl-aspartate. x axis
represents chemical shift in parts per million (ppm), y axis represents signal intensity in arbitrary units.
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parameters. Shapiro–Wilk test was used to assess normality. Categorical
variables were compared with Fisher’s exact test, while continuous
variables were compared with Student’s t test/analysis of variance or
Mann–Whitney U test/Kruskal–Wallis test for parametric and non-
parametric comparisons, respectively. Prognostic performance of the
metabolite ratios showing significant association with outcome was
evaluated by receiver-operating characteristics (ROC) analysis. Repeated-
measures linear mixed-effect regression model, with first-order autore-
gressive within-group correlation structure fitted by maximizing the
restricted log-likelihood, was performed to assess metabolite dynamics,
with metabolite ratios as dependent variables and postnatal age,
gestational age, and neurological outcome as predictors. Demographic,
clinical, and spectral data were analyzed using the IBM SPSS Statistics
software version 23.0.0.0 (IBM Corporation, Armonk, NY), as well as R
Statistical software 4.0.2 (R Core Team, Vienna, Austria).
RESULTS
One hundred and sixty-nine neonates with moderate-to-severe
HIE met the inclusion criteria, and were enrolled in our study.
Patient selection is presented on Fig. 1. From this patient pool, 129
newborns had only 1 initial H-MRS scan, 30 newborn had a total of
2 scans, and 8 newborn had 3 scans, summing to a total of 214
H-MRS results. Initial scans were performed on median DOL 4,
second scans on median DOL 7, and the third scans on median
DOL 8. Exact metabolite ratios for newborns having multiple
H-MRS scans are presented in the Supplementary Table.
A total of 7 newborns were excluded due to lack of
hypothermia treatment as per protocol: 1 infant did not receive
cooling as it was not yet adopted as a standard center practice in
2008, 1 infant received hypothermia with late onset (9 h of life)
due to logistical reasons, and 5 newborns suffered postpartum
asphyxia treated with altered hypothermia protocols. All other 169
infants enrolled received therapeutic hypothermia per protocol.
Ninety-six of the 169 patients had the H-MRS examination
performed while receiving whole-body hypothermia; the remain-
ing 73 patients were scanned under normothermic conditions,
after the completion of hypothermia treatment. All newborns with
early (DOL 1–3) H-MRS scans had the examination under
hypothermic conditions, and 6 newborns with midtime (DOL
4–6) H-MRS scan were examined during ongoing hypothermic
treatment.
A total of 69 patients had poor outcome, among whom 25 died,
all during the neonatal period. Of the 44 newborns who survived
but presented with poor outcome, MDI <70 was registered in 40
cases, whereas PDI <70 in 37 cases (both scores where <70 in 35
cases). Cerebral palsy was diagnosed in 21 cases, and 1 child
presented with bilateral sensorineural hearing loss.
Clinical data of newborns are presented in Table 1 according to
postnatal age category at initial H-MRS, as well as in Table 2,
sorted according to the number of performed H-MRS
examinations.
Analysis of the association between metabolite ratios and
outcome across all three postnatal age categories revealed that
only NAA/Cr peak height ratio and mI/NAA peak height ratio and
peak area ratio were able to consistently differentiate between
outcomes throughout early, midtime, and late postnatal age
windows as well. Detailed results of the performed Mann–Whitney
Table 1. Clinical characteristics of newborns enrolled in the study, categorized by postnatal age at initial scan.
Early H-MRS (DOL 1–3),
n= 91
Midtime H-MRS (DOL 4–6),
n= 50
Late H-MRS (DOL 7–14),
n= 28
p value
Male sex, % 63% 37% 61% 0.071
Gestational age (weeks) 39 [38; 40] 40 [39; 40] 39 [37; 40] 0.298
Birth weight (g) 3175 ± 521 3321 ± 542 3082 ± 528 0.126
Apgar 1’ 2 [0; 3] 2 [1; 4] 2 [1; 5] 0.425
Apgar 5’ 4 [3; 6] 5 [3; 6] 5 [3; 7] 0.107
Apgar 10’ 5 [4; 7] 6 [5; 7] 5 [4; 7] 0.758
Onset of hypothermia (h) 1.8 [1.2; 2.5] 2.1 [1.4; 2.6] 1.8 [1.0; 2.7] 0.439
Lowest pH <1 h of age 7.03 ± 0.20 7.04 ± 0.18 6.96 ± 0.24 0.202
Highest BD <1 h of age 17.7 ± 6.2 16.1 ± 6.7 16.5 ± 7.0 0.352
Neurology
Clinical or aEEG seizures (<24 h) 59% 56% 39% 0.173
Abnormal aEEG pattern (DNV, BS, LV, FT) 98% 94% 96% 0.506
aEEG normalization (CNV) <72 h 38% 58% 43% 0.805
aEEG normalization time (h) 20 [7; 44] 14 [10; 32] 10 [5;41] 0.533
Severity of encephalopathy (severe)a 85% 68% 71% 0.054
Cardiorespiratory status and multiorgan failure
Need for invasive ventilationb 93% 94% 93% 0.980
Length of invasive ventilation (days) 4 [4; 5] 5 [4; 5] 5 [5; 7] 0.018*
Need for cardiovascular supportc 65% 74% 82% 0.172
Length of cardiovascular support (h)d 67 [40; 146] 135 [74; 197.5] 163 [60; 229] 0.002*
Data shown as median [IQR], mean ± SD, or percentage.
BD base deficit, aEEG amplitude-integrated electroencephalography, BS burst suppression, LV low voltage, FT flat trace, CNV continuous normal voltage, DNV
discontinuous normal voltage.
*Bold figures represent significant results of chi-square test, ANOVA, or Kruskal–Wallis test (p < 0.05).
aModerate and severe encephalopathy defined using the modified Sarnat aEEG score10, as follows: moderate encephalopathy DNV on <6 h aEEG AND Sarnat
stage 1–2, severe encephalopathy: BS, LV, or FT on <6 h aEEG OR Sarnat 3.
bSIMV (synchronized intermittent mandatory ventilation), SIPPV (synchronous positive pressure ventilation) or HFO (high frequency oscillatory ventilation).
cDobutamine, dopamine, norepinephrine, epinephrine or milrinone infusion, or hydrocortisone supplementation.
dCalculated by summing up the length for the different vasoactive medications, in hours.
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U test are presented in Table 3 and Fig. 3. ROC analysis showed
that the highest predictive value could be observed in the late
(DOL ≥ 7) postnatal age window for both NAA/Cr peak height and
mI/NAA peak height and peak area ratios. Overall predictive value
was higher for mI/NAA height ratio than for mI/NAA area ratio
(calculated as a sum of areas under the ROC curve across postnatal
age categories), therefore we aimed the mixed-effect regression
model on NAA/Cr height ratio and mI/NAA height ratio. Detailed
results of the performed Mann–Whitney U test and ROC analysis
are displayed in Table 4.
A mixed-effect regression model was constructed to investigate
metabolite dynamics in the whole patient population, using NAA/
Cr and mI/NAA height ratios as dependent variables and
gestational age, postnatal age and neurological outcome as
predictors. Ongoing hypothermia treatment was not included as a
covariate, as it is coincidental with postnatal age during the first 3
postnatal days, due to the therapeutic hypothermia protocol
(onset of hypothermia <6 postnatal hours, duration of hypother-
mia 72 h)8. We found that, overall in the whole study population,
outcome was the only significant covariate for both metabolite
ratios, suggesting that these metabolite ratios are not affected by
gestational age and postnatal age.
However, analyzing the mixed-effect model separately in the
two outcome groups revealed that both NAA/Cr and mI/NAA
ratios are significantly affected by gestational age in the good
outcome group, but this association disappears in the
poor outcome group. In case of postnatal age though, in the
good outcome group, mI/NAA metabolite ratio proved to be
highly associated with postnatal age but not NAA/Cr. In the poor
outcome group, NAA/Cr showed only slight association with
postnatal age, whereas mI/NAA none. Results of the regression
analysis are presented in Table 5.
DISCUSSION
To the best of our knowledge, this is the first study to examine the
effect of postnatal age on the predictive value of brain H-MRS in
newborns with HIE throughout the first 2 weeks of life, as well as
the combined effect of gestational age, postnatal age, and
outcome on metabolite ratios. Our findings suggest that H-MRS
is a valuable predictive tool throughout the examined postnatal
age windows—the first 14 days of life—with the highest
predictive power between postnatal days 7–14, for the metabolite
ratios showing the strongest prognostic power, namely, NAA/Cr
and mI/NAA ratios. Moreover, these two metabolite ratios showed
the strongest association with neurodevelopmental outcome and
were not significantly affected by gestational age and postnatal
age, overall.
In our previous study, assessment of early (first 96 h of life),
conventional H-MRS concluded that, other than having predictive
power, NAA/Cr, NAA/Cho, and mI/NAA show weak correlation with
postnatal age at scan during first 4 days of life, hence might be
considered relatively stable in this early postnatal age period9.
However, no examination has been performed concerning the
postnatal age dependence of these metabolite ratios in the later
postnatal period. In the current research, we hypothesized that
after being relatively stable in the first 4 days of life, dynamic
changes of these metabolite ratios do appear in the later time
Table 2. Clinical characteristics of newborns, categorized by postnatal age at initial scan.
Single H-MRS performed, n= 135 Multiple (2 or 3) H-MRS performed, n= 34 p value
Male sex, % 58% 62% 0.702
Gestational age (weeks) 40 [38; 40] 39 [38; 40] 0.535
Birth weight (g) 3230 ± 510 3090 ± 600 0.179
Apgar 1’ 1 [0; 4] 2 [1; 4] 0.100
Apgar 5’ 5 [3; 6] 4 [3; 6] 0.998
Apgar 10’ 5 [4; 7] 5 [4; 7] 0.915
Onset of hypothermia (h) 1.8 [1.2; 2.6] 1.8 [1.2; 2.8] 0.673
Lowest pH <1 h of age 7.01 ± 0.21 7.07 ± 0.17 0.135
Highest BD <1 h of age 17.0 ± 6.6 17.1 ± 6.1 0.946
Neurology
Clinical or aEEG seizures (<24 h) 67% 85% 0.527
Abnormal aEEG pattern (DNV, BS, LV, FT) 95% 100% 0.601
aEEG normalization (CNV) <72 h 72% 72% >0.999
aEEG normalization time (h) 14 [7; 36] 36 [12; 44] 0.250
Severity of encephalopathy (severe)a 75% 88% 0.111
Cardiorespiratory status and multiorgan failure
Need for invasive ventilationb 93% 97% 0.696
Length of invasive ventilation (days) 5 [4; 5] 4 [4; 5] 0.601
Need for cardiovascular supportc 70% 71% >0.999
Length of cardiovascular support (h)d 116 [60; 206] 64 [31; 131] 0.004*
Data shown as median [IQR], mean ± SD, or percentage.
BD base deficit, aEEG amplitude-integrated electroencephalography, DNV discontinuous normal voltage, BS burst suppression, LV low voltage, FT flat trace, CNV
continuous normal voltage, DNV discontinuous normal voltage.
*Bold figures represent significant results of chi-square test, ANOVA, or Kruskal–Wallis test (p < 0.05).
aModerate and severe encephalopathy defined using the modified Sarnat aEEG score10, as follows: moderate encephalopathy DNV on <6 h aEEG AND Sarnat
stage 1–2, severe encephalopathy: BS, LV, or FT on <6 h aEEG OR Sarnat 3.
bSIMV (synchronized intermittent mandatory ventilation), SIPPV (synchronous positive pressure ventilation) or HFO (high frequency oscillatory ventilation).
cDobutamine, dopamine, norepinephrine, epinephrine or milrinone infusion, or hydrocortisone supplementation.
dCalculated by summing up the length for the different vasoactive medications, in hours.
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periods, potentially modifying their predictive power. Our results
suggest that, whereas prognostic accuracy of these metabolite
ratios varies with age, NAA/Cr and mI/NAA keep their predictive
power throughout the first 14 days of life, making them optimal
for prediction.
The physiological and gestational age-related variability of
metabolite levels in healthy fetuses has been previously described
in detail. According to Urbanik et al., a significant rise can be
detected in NAA, Cr, Cho, and mI absolute concentrations
throughout gestation (weeks 18–40)7. This observation is partly
confirmed by Kok et al., also describing increasing NAA absolute
levels between gestational weeks 30–41, further adding that,
while NAA/Cr and NAA/Cho ratios also rise in the examined
gestational period, Cho/Cr ratio decreases, suggesting that



























































































































































































































































































































































































































































































































































































































































































































































Fig. 3 H-MRS metabolite ratios showing association with outcome
across all postnatal age categories (postnatal days 0–14),
categorized by outcome and postnatal age category. Bars
represent medians, error bars represent interquartile ranges. mI
myo-inositol, NAA N-acetyl aspartate, DOL day of life.
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the same velocity throughout physiological neuronal
maturation13.
The results of our mixed-effect regression model propose that,
when outcome is taken into consideration as a covariate, neither
gestational age nor postnatal age have a significant effect on
NAA/Cr and mI/NAA metabolite ratios. This suggests that the
moderate-to-severe hypoxic–ischemic injury has such a definitive
impact on brain metabolism (and consequently, metabolite levels
and ratios) that the influence of other modifying factors like
gestational age or postnatal age disappears.
However, when these associations were analyzed in the good
outcome group alone, it was revealed that these metabolite ratios
are greatly influenced by gestational age—similar to healthy
newborn conditions—represented by a rise in NAA/Cr ratio and a
decrease in mI/NAA ratio, as gestational age increases. Addition-
ally, in the good outcome group, postnatal age turned out to be a
significant covariate, but only for mI/NAA, represented by a
decrease in mI/NAA with increasing postnatal age. This might
imply that, in case of newborns facing good outcome, the
physiological, gestational age-dependent variability of metabolite
levels can be observed, despite the HIE (presumably due to having
undergone milder neuronal injury). Moreover, in case of mI/NAA,
signs of postnatal age-dependent metabolic variability also
emerged.
Based on our observation, in the poor outcome group though,
the effect of gestational age on metabolite ratios disappeared,
suggesting that the more severe metabolic changes caused by a
more intense hypoxic–ischemic insult may obscure the physiolo-
gical pattern evolution of metabolites. Furthermore, the effect of
postnatal age on mI/NAA ratio also vanished, whereas NAA/Cr
ratio presented an although significant but slight association with
postnatal age.
A number of existing research papers studying H-MRS as a
prognostic tool in HIE use various methods for data optimization
(e.g., custom made headcoil, absolute quantification sequences,
post-processing techniques)14–16. These methods enable the
accurate detection and measurement of the lactate (Lac)
metabolite peak, making Lac and Lac-derived ratios (Lac/NAA,
Lac/Cr, Lac/Cho) also among the most widely analyzed metabo-
lites for prediction. While the above listed methods may indeed
improve data quality, these methods may not be generally
applicable in all clinical settings, especially in those with low
resources. Our aim was to assess whether H-MRS is an adequate
prognostic tool, as well as to describe the dynamics of
conventional H-MRS, throughout the first 14 days of newborns
with HIE, for our conclusions to be applicable in every clinical
setting. Nevertheless, based on our previous study, Lac peak
cannot be accurately detected under conventional conditions, due
to high noise levels9. Additionally, it has been previously described
that at 3 T and moderate TE (e.g., 144 ms), Lac peak suffers signal
loss and may not be detectable due to anomalous j-coupling17.
Also, Wu et al. found that in newborns with moderate and severe
HIE, cerebral Lac concentrations peak early in all examined
cerebral regions (basal ganglia, thalamus, cortex, and white
matter) and, in most cases, fall in the normal range after postnatal
days 4–518. Moreover, recent evidence suggests that Lac ceases to
be an accurate H-MRS predictor, when analyzed in newborns
treated with therapeutic hypothermia, an observation presumably
indicating the working mechanism of hypothermic treatment for
HIE19,20. Conclusively, for the sake of our initial aim, we excluded
Lac from the list of our metabolite ratio candidates.
While NAA and NAA/Cr ratio are extensively studied biomarkers,
few studies focus on mI and its significance in HIE21. mI, as a
conformation isomer of the pentose sugar inositol, is one of the
main osmolites of human cells, as well as an intracellular signal
transmitter and precursor molecule for lipid synthesis. During
gestation and maturation, its level rises around term (with
ongoing myelination), being one of the highest peaks in the
neonatal period, and then rapidly decreases with age, reaching its
final level around 1 year of age. Being a membrane compound, its
level significantly rises after neuronal injuries, suggesting cell
death22,23.
Current guidelines for management of HIE recommend the
performance of more than one MR examination12, considering
that the utility and sensitivity of its various imaging modalities
change with the postnatal age of the newborns—conclusively,
H-MRS of asphyxiated newborns is also performed at various
postnatal ages. Moreover, H-MRS examination of all newborns
with HIE in a uniform postnatal narrow age window is not
possible, due to the variable clinical stability of neonates with HIE,
as well as resource availability. This further emphasizes the
importance of detailed description of how postnatal age affects
metabolite ratios and, more importantly, their predictive power.
According to our study, it seems that H-MRS examination keeps its
outstanding predictive value throughout the first 14 days of life in
newborns with HIE. Therefore, performing an additional H-MRS
sequence whenever a brain MRI examination is done provides
valuable additional diagnostic and prognostic information to the
clinician.
Limitations
Despite our careful preparation of our study methodology, there
are limitations that should be taken into consideration. The
general limitation of our study is the lack of healthy, gestational
age-specific reference data from the first 2 weeks of the neonatal
period. However, this would be an unrealistic expectation, from
both ethical and methodological reasons, and theoretically, this
missing referential data is not indispensable for prognostication.
The other limitation is the retrospective nature of the study. On
the one hand, this is a limitation compared to a prospective study
Table 4. Results of Mann–Whitney U test comparison of metabolite ratios and outcome, across postnatal age categories at H-MRS scan, as well as
receiver-operating characteristics (ROC) analysis of metabolite ratios.
Early H-MRS (DOL 1–3) Midtime H-MRS (DOL 4–6) Late H-MRS (DOL ≥7)
AUC Cutoff SENS SPEC AUC Cutoff SENS SPEC AUC Cutoff SENS SPEC
NAA/Cr height 0.807 0.96 81.8% 70.2% 0.871 0.95 81.1% 84.6% 0.963 0.83 88.9% 88.9%
NAA/Cr area 0.733 0.99 70.5% 68.1% 0.65 0.69 97.3% 46.2% 0.895 0.78 94.4% 77.8%
NAA/Cho height 0.601 0.85 77.3% 48.9% 0.63 0.69 86.5% 53.8% 0.735 0.54 88.9% 66.7%
NAA/Cr area 0.604 0.59 84.1% 42.6% 0.84 0.65 78.4% 84.6% 0.883 0.45 94.4% 77.8%
mI/NAA height 0.719 0.42 59.0% 82.6% 0.897 0.37 63.6% 99.9% 0.816 0.42 73.7% 75.0%
mI/NAA area 0.683 0.80 69.2% 72.7% 0.818 0.85 84.8% 70.0% 0.816 0.93 99.9% 62.5%
AUC area under ROC curve, SENS sensitivity, SPEC specificity.
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with fine-tuned imaging and clinical parameters for research
purposes; however, on the other hand, this could be viewed as a
strength from a clinical point of view, having relied on data
obtainable from any MR facility dealing with asphyxiated
neonates, thus being more generalizable. Furthermore, due to
resource availability, two different 3 Tesla MRI scanners were used
to examine our patient population. While this might bias the
acquired spectral data, this technical issue is counteracted by the
identical magnetic field strength of the scanners, as well as our
assessment of metabolite ratios instead of absolute metabolite
levels. Our results could also be biased by the uneven sample sizes
of our patient groups, which may decrease the accuracy of our
statistical analysis. Another potential limitation might be the fact
that a large number of patients were unavailable to follow-up and
had to be excluded from the outcome analysis. However, clinical
parameters of surviving newborns lost to follow-up did not differ
significantly from those with follow-up results (data not shown),
therefore a systematic bias is unlikely. Moreover, the establish-
ment of postnatal age categories by itself, for analysis of
prognostic performance of HMRS, can be considered a limitation,
since it inevitably creates artificial conditions. While assessment of
postnatal age at scan in considerably smaller age categories (i.e., 6
or 12-h periods) or as a continuous variable would be less artificial
and more accurate approach to determine predictive value during
the examined postnatal period, that would require such a large
sample size that might only be feasible in a future multicenter
study. Therefore, prompted by our results, we seek to outline and
conduct such a future study in a larger population and on other
vendors’ MR scanner, as well as to compare the predictive value
for 2-year neurological outcome with that for longer-term (i.e., 7
and 14 years of age) neurodevelopmental outcome, in order to
refine and optimize the prognostic power of conventional H-MRS.
CONCLUSION
In summary, we propose that conventional brain H-MRS
examination has consistently high prognostic value for metabolite
ratios NAA/Cr and mI/NAA throughout the first 2 postnatal weeks
of newborns with HIE, with the highest predictive power between
postnatal days 7–14. Moreover, actual metabolite ratios show the
strongest association with the long-term outcome and are not
overall significantly affected by gestational age and postnatal age.
This implies that, while assessed separately in the outcome
groups, gestational age and postnatal age-dependent metabolite
variations do appear, and these are strongly outweighed by the
consequential outcome, presumably determined by severity of
insult.
REFERENCES
1. Mcintyre, S., Badawi, N., Blair, E. & Nelson, K. B. Does aetiology of neonatal
encephalopathy and hypoxic-ischaemic encephalopathy influence the outcome
of treatment? Dev. Med. Child Neurol. 57, 2–7 (2015).
2. Hassell, K. J., Ezzati, M., Alonso-Alconada, D., Hausenloy, D. J. & Robertson, N. J.
New horizons for newborn brain protection: enhancing endogenous neuropro-
tection. Arch. Dis. Child. Fetal Neonatal Ed. 100, F541–F552 (2015).
3. Hankins, G. D. V. & Speer, M. Defining the pathogenesis and pathophysiology of
neonatal encephalopathy and cerebral palsy. Obstet. Gynecol. 102, 628–636
(2003).
4. Lally, P. J. et al. Magnetic resonance spectroscopy assessment of brain injury after
moderate hypothermia in neonatal encephalopathy: a prospective multicentre
cohort study. Lancet Neurol. 18, 35–45 (2019).
5. Thayyil, S. et al. Cerebral magnetic resonance biomarkers in neonatal encepha-
lopathy: a meta-analysis. Pediatrics 125, e382–e395 (2010).
6. Shibasaki, J. et al. Changes in brain metabolite concentrations after neonatal
hypoxic-ischemic encephalopathy. Radiology 288, 840–848 (2018).
7. Urbanik, A., Cichocka, M., Kozub, J., Karcz, P. & Herman-Sucharska, I. Evaluation of
changes in biochemical composition of fetal brain between 18th and 40th
gestational week in proton magnetic resonance spectroscopy. J. Matern. Fetal
Neonatal Med. 32, 2493–2499 (2019).
8. Azzopardi, D. et al. The TOBY Study. Whole body hypothermia for the treatment
of perinatal asphyxial encephalopathy: a randomised controlled trial. BMC Pediatr.
8, 17 (2008).
9. Barta, H. et al. Prognostic value of early, conventional proton magnetic
resonance spectroscopy in cooled asphyxiated infants. BMC Pediatr. 18, 302
(2018).
10. Shalak, L. F., Laptook, A. R., Velaphi, S. C. & Perlman, J. M. Amplitude-integrated
electroencephalography coupled with an early neurologic examination enhances
prediction of term infants at risk for persistent encephalopathy. Pediatrics 111,
351–357 (2003).
11. Bottomley, P. A. The trouble with spectroscopy papers. Radiology 181, 344–350
(1991).
12. The American Academy of Pediatrics. The American College of Obstetricians and
Gynecologists. Executive summary: Neonatal Encephalopathy and Neurologic
Outcome, Second Edition. Obstet. Gynecol. 123, 896–901 (2014).
13. Kok, R. D., van den Berg, P. P., van den Bergh, A. J., Nijland, R. & Heerschap, A.
Maturation of the human fetal brain as observed by 1H MR spectroscopy. Magn.
Reson. Med. 48, 611–616 (2002).
Table 5. Effect of gestational age, postnatal age, and neurological outcome on metabolite dynamics during the first 14 days of life.
NAA/Cr height mI/NAA height
Coefficient 95% CI p value Coefficient 95% CI p value
General
(Intercept) 0.4522 (−0.3335, 1.2379) 0.2574 1.1115 (−0.2324, 2.4553) 0.1043
Gestational age (weeks) 0.0162 (−0.0038, 0.0362) 0.1115 −0.0177 (−0.0519, 0.0165) 0.3086
Postnatal age (days) −0.0450 (−0.1015, 0.0114) 0.1148 −0.0467 (−0.1224, 0.0291) 0.2209
Poor outcome −0.2277 (−0.2883, −0.1672) 0.0000* 0.3167 (0.2125, 0.4208) 0.0000*
Good outcome group
(Intercept) −0.1929 (−1.0761, 0.6902) 0.6656 1.8131 (1.1285, 2.4978) 0.0000
Gestational age (weeks) 0.0320 (0.0095, 0.0545) 0.0058* −0.0346 (−0.0521, −0.0171) 0.0002*
Postnatal age (days) −0.0038 (−0.0723, 0.0646) 0.9088 −0.1047 (−0.1601, −0.0494) 0.0007*
Poor outcome group
(Intercept) 0.7541 (−0.5712, 2.0795) 0.2600 0.5655 (−2.3818, 3.5128) 0.7025
Gestational age (weeks) 0.0032 (−0.0310, 0.0374) 0.8513 0.0039 (−0.0723, 0.0802) 0.9182
Postnatal age (days) −0.0958 (−0.1824, −0.0091) 0.0319* 0.0151 (−0.1133, 0.1435) 0.8083
Results of mixed-effect regression models are shown, presented overall in the whole study population and separately in the good and poor outcome groups.
95% CI confidence interval (at 95% confidence level).
*Bold figures represent significant results (p < 0.05).
H. Barta et al.
8
Pediatric Research
14. Cheong, J. L. Y. et al. Proton MR spectroscopy in neonates with perinatal
cerebral hypoxic-ischemic injury: metabolite peak-area ratios, relaxation times, and
absolute concentrations. AJNR Am. J. Neuroradiol. 27, 1546–1554 (2006).
15. Alderliesten, T. et al. MRI and spectroscopy in (near) term neonates with perinatal
asphyxia and therapeutic hypothermia. Arch. Dis. Child. Fetal Neonatal Ed. 102,
F147–F152 (2017).
16. van Doormaal, P. J., Meiners, L. C., ter Horst, H. J., van der Veere, C. N. & Sijens, P. E.
The prognostic value of multivoxel magnetic resonance spectroscopy determined
metabolite levels in white and grey matter brain tissue for adverse outcome in
term newborns following perinatal asphyxia. Eur. Radiol. 22, 772–778 (2012).
17. Lange, T. et al. Pitfalls in lactate measurements at 3T. AJNR Am. J. Neuroradiol. 27,
895–901 (2006).
18. Whu, T. W. et al. Cerebral lactate concentration in neonatal hypoxic-ischemic
encephalopathy: in relation to time, characteristic of injury, and serum lactate
concentration. Front. Neurol. 11, 293 (2018).
19. Sijens, P. E., Wischniowsky, K. & ter Horst, H. J. The prognostic value of proton
magnetic resonance spectroscopy in term newborns treated with therapeutic
hypothermia following asphyxia. Magn. Reson. Imaging 42, 82–87 (2017).
20. Erecinska, M., Thoresen, M. & Silver, I. A. Effects of hypothermia on energy
metabolism in mammalian central nervous system. J. Cereb. Blood Flow Metab.
23, 513–530 (2003).
21. Robertson, N. J. et al. Early increases in brain myo-inositol measured by proton
magnetic resonance spectroscopy in term infants with neonatal encephalopathy.
Pediatr. Res. 50, 692–700 (2001).
22. Macrì, M. A. et al. Regional changes in the metabolite profile after long-term
hypoxia-ischemia in brains of young and aged rats: a quantitative proton MRS
study. Neurobiol. Aging 27, 98–104 (2006).
23. Brighina, E., Bresolin, N., Pardi, G. & Rango, M. Human fetal brain chemistry as
detected by proton magnetic resonance spectroscopy. Pediatr. Neurol. 40,
327–342 (2009).
ACKNOWLEDGEMENTS
We thank Laszlo Szakacs for his expert help with statistical analysis, as well as Gyula
Gyebnar and the MR operators for the technical help with the H-MRS acquisition
protocol. We also thank the medical and nursing team at the NICU of the 1st
Department of Paediatrics, Semmelweis University for the professional care. H.B. and
A.J. were supported by the Higher Education Institutional Excellence Program of the
Ministry for Innovation and Technology in Hungary, within the framework of the
Neurology thematic program of the Semmelweis University. H.B. was also supported
by the ÚNKP-20-4-I New National Excellence Program of the Ministry for Innovation
and Technology from the source of the National Research, Development and
Innovation Fund (ÚNKP-20-4-I-SE-8). A.J. was also supported by the Hungarian
Academy of Science, Premium Postdoctoral Fellowship (PPD460004). Neither funding
source had any role in the design of the study, collection and analysis of data, and
decision to publish.
AUTHOR CONTRIBUTIONS
H.B. acquired clinical and radiological patient information and finalized and
interpreted the analysis of data, as well as drafted the manuscript. A.J. participated
in the conception of the study, outlined the statistical analysis, and critically revised
the statistical analysis and the manuscript language. L.K. and N.S. participated in the
acquisition and interpretation of H-MRS data. G.R. contributed to the outline of the
methods and aims of the study and participated in the analysis and interpretation of
results. M.S. was responsible for the conception and analysis and interpretation of
data for the work. All authors read and approved the final manuscript.
FUNDING
Open access funding provided by Semmelweis University.
COMPETING INTERESTS
The authors declare no competing interests.
PATIENT CONSENT
Consent was obtained from parents/legal guardians of all newborns participating in
our study. Ethical permission for the analysis was obtained from the Scientific and
Medical Research Council Ethics Committee of Hungary (11790-2/2016/EKU).
ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41390-021-01626-z.
Correspondence and requests for materials should be addressed to Hajnalka Barta.
Reprints and permission information is available at http://www.nature.com/
reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2021
H. Barta et al.
9
Pediatric Research
